I’m a type 1 diabetic, I’ve been using insulin pumps and CGM for over a decade. I am in no way defending pump manufacturers but A, this is not “basic medical care”, pump/CGM systems (closed loop as they are called) capable of maintaining blood sugar levels are the latest and greatest tech for insulin dependent diabetics. B, it’s not like they are creating something that doesn’t already exist, they are just making open source alternatives, which I heartily support.
I just don’t like how you are making it sound like “Welp the medical community doesn’t want to make them so people had to step up and do it themselves!”
These things have been around a few years now and while I could fill a book with complaints about the design choices of the hardware we rely on I gotta say the algorithms that the software uses is very far down on the list of issues.
Apologies if I sounded flippant. The first part of the article made it sound to me like companies weren’t developing this with any real urgency, hence why they had to do it themselves:
They knew that a fairly straightforward piece of software could make their lives much easier, but no companies were developing it quickly enough.
And I suppose what I meant by “basic medical care” is more that, at least to the extent I am aware of, the medical community is well-versed in how to manage the issue, and with the amount of people who suffer from T1 diabetes and the rapid rate of technological progression in society in general, these solutions should not only already be available but should be available to everyone, and shouldn’t be as expensive to manage as it is. Near the end of the article is the comment:
A team at the University of Otago in New Zealand has run a successful early-stage clinical trial of an open-source insulin pump. The goal is to provide free-of-charge design plans to qualified manufacturers to build pumps for a fraction of the cost of current commercial ones.
I suppose it just upsets me in general that the goal of building low cost insulin pumps isn’t a globally shared one across manufacturers.
You are not logged in. However you can subscribe from another Fediverse account, for example Lemmy or Mastodon. To do this, paste the following into the search field of your instance: !technology@beehaw.org
A nice place to discuss rumors, happenings, innovations, and challenges in the technology sphere. We also welcome discussions on the intersections of technology and society. If it’s technological news or discussion of technology, it probably belongs here.
Remember the overriding ethos on Beehaw: Be(e) Nice. Each user you encounter here is a person, and should be treated with kindness (even if they’re wrong, or use a Linux distro you don’t like). Personal attacks will not be tolerated.
I’m a type 1 diabetic, I’ve been using insulin pumps and CGM for over a decade. I am in no way defending pump manufacturers but A, this is not “basic medical care”, pump/CGM systems (closed loop as they are called) capable of maintaining blood sugar levels are the latest and greatest tech for insulin dependent diabetics. B, it’s not like they are creating something that doesn’t already exist, they are just making open source alternatives, which I heartily support.
I just don’t like how you are making it sound like “Welp the medical community doesn’t want to make them so people had to step up and do it themselves!”
These things have been around a few years now and while I could fill a book with complaints about the design choices of the hardware we rely on I gotta say the algorithms that the software uses is very far down on the list of issues.
Apologies if I sounded flippant. The first part of the article made it sound to me like companies weren’t developing this with any real urgency, hence why they had to do it themselves:
And I suppose what I meant by “basic medical care” is more that, at least to the extent I am aware of, the medical community is well-versed in how to manage the issue, and with the amount of people who suffer from T1 diabetes and the rapid rate of technological progression in society in general, these solutions should not only already be available but should be available to everyone, and shouldn’t be as expensive to manage as it is. Near the end of the article is the comment:
I suppose it just upsets me in general that the goal of building low cost insulin pumps isn’t a globally shared one across manufacturers.